NEW ORLEANSHigh remission rates with extended survival are being achieved in patients who had failed all other therapies including allogeneic stem cell transplantation for their acute lymphoblastic leukemia and otherwise had very short life expectancies. Stephan A Grupp, MD, PhD from the University of Pennsylvania and his colleague Michael Kalos PhD discussed their findings from a study presented here of T-cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) which they found to have significant in vivo proliferation, produce complete responses and had long-term persistence without graft versus host disease in children and adults with relapsed, refractory disease. Laurence Cooper MD, PhD, of the M D Anderson Cancer Center in Houston moderator of a press briefing here on CAR T-cell therapy assessed the potential scope of this treatment in hematologic malignancy and solid tumors. George Canellos MD from the Dana-Farber Cancer Institute in Boston added his opinion about the value and application of this technology.
CONTACT:
Attending Physician
Director of Translational Research, Center for Childhood Cancer Research at The Children’s Hospital of Philadelphia
Medical Director, Stem Cell Laboratory
Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
Chair, Stem Cell Transplant Discipline, National Children’s Oncology Group
SOURCE:
American Society of Hematology Annual Meeting, New Orleans, December 6 – 10
Abstract number: 67
TITLE:
T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALLClinically
Program: Oral and Poster Abstracts
Type: Oral
Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Novel Immune-Based Therapies and Novel Targets
Sunday, December 8, 2013: 5:00 PM
La Nouvelle Ballroom C (Ernest N. Morial Convention Center)
Stephan A Grupp, MD, PhD1,2, Noelle V. Frey, MD3,4, Richard Aplenc, MD, PhD5,6, David M Barrett, MD/PhD1*, Anne Chew, PhD7*, Michael Kalos, PhD7, Bruce L. Levine, PhD7, Manuel Litchman, MD8*, Shannon L Maude, MD, PhD1, Susan R. Rheingold6, Angela Shen, MD8*, Christine Strait1*, David T. Teachey, MD9*, Patricia A. Wood, MD, PhD8, David Porter, MD2 and Carl H. June, MD7
1Division of Oncology, Children’s Hospital of Philadelphia, Philadelphia, PA
2Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
3Hematologic Malignancies Program, Hematology-Oncology Division, University of Pennsylvania, Philadelphia, PA
4Abramson Cancer Center, Philadelphia, PA
5Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA
6Division of Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA
7Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
8Novartis Pharmaceuticals Corporation, East Hanover, NJ
9Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, PA
LINK:
Web link:
https://ash.confex.com/ash/2013/webprogram/Paper60913.html